Inhibition of the activation of STAT3, e.g. by the anti-IL6R monoclonal antibody Tocilizumab, is known to down-regulate the immune suppression caused by tumor cells [41], and inhibition of IL-6 signaling may be a therapeutic for patients with cancer when IL-6 is over-expressed [28]. Here, STAT3 is linked to neoplasm.